Women living with HIV prefer long-acting injectable anti-retroviral therapy over daily pill

A new study found that the majority of women living with HIV would endorse a monthly long acting injectable (LAI) antiretroviral therapy over current daily pills. LAI HIV therapy has completed Phase III trials and is awaiting Food and Drug Administration approval. Over half of the women would choose LAI HIV therapy over daily pills for convenience, privacy, and perceived effectiveness. This study is the first to exclusively explore women’s interest in LAI HIV therapy.